Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
PedvaxHIB® Liquid[Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)]
Medication labelWhy this: Advisory · dailymed-other
Liquid PedvaxHIB is indicated for routine vaccination against invasive disease caused by Haemophilus influenzae type b in infants and children 2 to 71 months of age. Liquid PedvaxHIB will not protect against disease caused by Haemophilus influenzae other than type b or against other microorganisms that cause invasive disease such as meningitis or sepsis. As with any vaccine, vaccination with Liquid PedvaxHIB may not result in a protective antibody response in all individuals given the vaccine. BECAUSE OF THE POTENTIAL FOR IMMUNE TOLERANCE, Liquid PedvaxHIB IS NOT RECOMMENDED FOR USE IN INFANTS YOUNGER THAN 6 WEEKS OF AGE. (See PRECAUTIONS.) Infants completing the primary two-dose regimen before 12 months of age should receive a booster dose (see DOSAGE AND ADMINISTRATION).
- generic_name
- haemophilus b conjugate vaccine (meningococcal protein conjugate)
- product_names
- Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)
- ndc
- 0006-4897, 0006-4897-01, 0006-4897-00
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en